Zobrazeno 1 - 10 of 15 pro vyhledávání: '"Juan J. Gorgojo-Martinez"'
1
Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study
Autor: Almodóvar-Ruiz, Juan J. Gorgojo-Martinez, Pablo José Ferreira-Ocampo, Alba Galdón Sanz-Pastor, Jersy Cárdenas-Salas, Teresa Antón-Bravo, Miguel Brito-Sanfiel, Francisca
Publikováno v: Journal of Clinical Medicine; Volume 12; Issue 13; Pages: 4248
Aim: This study aimed to evaluate the effectiveness and tolerability of intensifying the dose of canagliflozin from 100 mg/day (CANA100) to 300 mg/day (CANA300) in patients with type 2 diabetes (T2DM) and suboptimal metabolic control in a real-world
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=multidiscipl::69e99736702979c28e46348fbd35100e
Zobrazit plný text záznamu
2
Real-World Clinical Outcomes Associated with Canagliflozin in Patients Aged 65 Years and Older with Type 2 Diabetes Mellitus in Spain: The Old Real-Wecan Study
Autor: Jaime E.M. Wong-Cruz, Miguel Brito-Sanfiel, Manuel Gargallo-Fernández, Teresa Antón-Bravo, Alba Galdón Sanz-Pastor, Juan J. Gorgojo-Martinez
Publikováno v: Diabetology
Volume 2
Issue 3
Pages 15-175
The observational Real-Wecan study showed that canagliflozin 100 mg (CANA100) as an add-on therapy, and canagliflozin 300 (CANA300), switching from prior SGLT-2i therapy, significantly improved several cardiometabolic parameters in patients with T2DM
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d35eaecd07a5ee24d1cb70947623cf8
https://doi.org/10.3390/diabetology2030015
Zobrazit plný text záznamu
3
1440-P: Effects of Two Weight-Loss Medications, Liraglutide and Orlistat, on Liver Enzymes in Patients with Overweight or Obesity in a Real-World Setting
Autor: JUAN J. GORGOJO-MARTINEZ, PABLO L. LOIS CHICHARRO, PABLO J. FERREIRA-OCAMPO, SANDRA C. DOEJO-MARCIALES, SOLANGE F. BARRA-MALIG, FRANCISCA ALMODOVAR-RUIZ
Publikováno v: Diabetes. 71
The aim of this analysis of the XENSOR study was to assess the effect of 2 weight-loss drugs on hepatic serum biomarkers in patients with overweight or obesity and insufficient weight loss (WL) after a lifestyle modification program. A retrospective
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::562402aeb874f88f2860624e362b4b41
https://doi.org/10.2337/db22-1440-p
Zobrazit plný text záznamu
4
Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study
Autor: Vittal Hejjaji, Juan J. Gorgojo‐Martinez, Fengming Tang, Julia Blanco Garnelo, Andrew Cooper, Jesús Medina, Miren Sequera Mutiozabal, Kamlesh Khunti, Antonio Nicolucci, Marina V. Shestakova, Linong Ji, Marilia B. Gomes, Hirotaka Watada, Jiten Vora, Ali O. Malik, Mikhail Kosiborod, Suzanne V. Arnold
Publikováno v: Diabetes, obesitymetabolismREFERENCES. 24(9)
To estimate real-world change in weight over 3 years and the factors influencing it in participants who are overweight and live with type 2 diabetes.DISCOVER is a multinational prospective observational study that enrolled participants with type 2 di
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2434a614afae5019aa72df2f1817eee
https://pubmed.ncbi.nlm.nih.gov/35546275
Zobrazit plný text záznamu
5
Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study
Autor: Juan J. Gorgojo-Martinez, Miguel Brito-Sanfiel, Teresa Antón-Bravo, Alba Galdón Sanz-Pastor, Jaime Wong-Cruz, Manuel A. Gargallo Fernández
Publikováno v: Journal of Clinical Medicine; Volume 11; Issue 19; Pages: 5622
The Real-WECAN study evaluated the real-life effectiveness and safety of canagliflozin 100 mg daily (initiated in SGLT-2 inhibitors naïve patients) and canagliflozin 300 mg daily (switching from canagliflozin 100 mg or other SGLT-2 inhibitors) in in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f6e5db55329d7078ae7b2aacee00720
https://doi.org/10.3390/jcm11195622
Zobrazit plný text záznamu
6
797-P: Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-WECAN Study
Autor: Jaime E.M. Wong-Cruz, Teresa Antón-Bravo, Manuel Gargallo-Fernández, Juan J. Gorgojo-Martinez, Miguel Brito, Alba Galdon-Sanzpastor
Publikováno v: Diabetes. 70
The Real-WECAN study assessed in a real-world setting the efectiveness and safety of canagliflozin 100 mg (add-on therapy in SGLT-2i naive individuals) and canagliflozin 300 mg (switching from canagliflozin 100 mg or other SGLT-2i) in patients with T
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f8fc642cf5e4df7d06bdcfa96f2322ac
https://doi.org/10.2337/db21-797-p
Zobrazit plný text záznamu
7
Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
Autor: Jaime E.M. Wong-Cruz, Miguel Brito-Sanfiel, Manuel Gargallo-Fernández, Alba Galdón Sanz-Pastor, Teresa Antón-Bravo, Juan J. Gorgojo-Martinez
Publikováno v: Journal of Clinical Medicine
Volume 9
Issue 7
Journal of Clinical Medicine, Vol 9, Iss 2275, p 2275 (2020)
The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as an add-on to the background antihyperglycemic therapy, and to evaluate the intensification of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d33705a2fe17cf8fa45f984b16ced3c4
Zobrazit plný text záznamu
8
1127-P: Real-World Clinical Outcomes Associated with Canagliflozin 100mg and with Intensification of SGLT2 Inhibitor Therapy Switching to Canagliflozin 300mg in Patients with Type 2 Diabetes Mellitus: The Real-WECAN Study
Autor: Teresa Antón-Bravo, Juan J. Gorgojo-Martinez, Miguel Brito-Sanfiel, Jaime E.M. Wong-Cruz, Manuel Gargallo-Fernández, Alba Galdon
Publikováno v: Diabetes. 69
The aims of this multicentric retrospective study were to assess in a real-world setting the effectiveness and safety of canagliflozin 100 mg/d (CANA100) as add-on to the background antihyperglycemic therapy, and to evaluate the intensification of SG
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::84645583b35bf0ec3626c1501b01c2a5
https://doi.org/10.2337/db20-1127-p
Zobrazit plný text záznamu
10
2049-P: Real-World Assessment of Orlistat and Liraglutide in Patients with Obesity: The XENSOR Study
Autor: Clara Serrano-Moreno, Almodóvar-Ruiz Francisca, Juan J. Gorgojo-Martinez, Alberto Sanz-Velasco, Basagoiti-Carreño Belen
Publikováno v: Diabetes. 68
Data on comparative effectiveness among weight-loss medications (WLMs) in real-world studies (RWS) are limited. The aim of the XENSOR study was to assess in a real-world setting the effectiveness of two WLMs, orlistat and liraglutide, in patients wit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abafcc290e8c7a1bb224c51fe954c1d2
https://doi.org/10.2337/db19-2049-p
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje